The partner network reflects the expertise necessary to ensure optimal project development and exit.
Former Senior Vice President Finance & Business Administration of Pharmacia Consumer Healthcare. Chairman of Adenovir Pharma AB. Former chairman of Ambria Dermatology AB and board member of LIDDS AB.
B.Sc. (Econ), J.D, LL.M. Chairman of Xintela AB, Monocl AB, Saga Diagnostics AB and ImmuneBiotech Medical AB. Partner of Business Research Life Sciences Ltd. Advisor to pharmaceutical, biotech, medical device and other high technology companies. Former project leader of DuoCort AB and AcuCort AB. Innovator in Laccure AB and Trophea AB.
Professor of Endocrinology, Sahlgrenska Academy, University of Gothenburg and previous Head of Department of Internal Medicine, Sahlgrenska University Hospital. Co-founder of biotech company Tercica CA, US. Chairman of Oncorena Holding AB.
MD, PhD, Professor, Deputy Head of the Institute for Clinical Sciences and Head of the Orthopaedic Department at the Sahlgrenska Academy, University of Gothenburg. Senior Consultant in orthopaedics, specializing in spine surgery, at the Department of Orthopaedics, Sahlgrenska University Hospital, Gothenburg. Author of more than 80 peer-reviewed articles mainly in the field of back and neck pain related conditions, including both laboratory, experimental, clinical and registry studies.
PhD, former Senior Vice President Corporate Development at Biovitrum and Vice President Global Licensing at Pharmacia. Board member of AcuCort AB, Adenovir Pharma AB and Laccure AB.
Robert JM Brummer
MD, PhD, Professor of Gastroenterology and Clinical Nutrition, Director Nutrition-Gut-Brain Interactions Research Center. Pro-Vice-Chancellor Internationalisation, External Relations and Innovation at Örebro University since 2016. Engagement in several national and international board/expert/review functions within the domain of gastrointestinal and nutritional sciences, agro-food and nutritional innovation. Chairman of the Board of Örebro University Holding AB and representative of Örebro University in a number of national and international organisations.
MD, PhD, Professor in Pediatrics, Head of Pediatric Department at the Sahlgrenska Academy, University of Gothenburg and senior consultant at the Queen Silvia Children's Hospital, where she holds a board member position at the board of the hospital.
Dahlgren is Director of the internationally well-known Gothenburg Pediatric Growth Research Center. Her research is focused towards non-conventional innovative treatment modalities and personalized medicine in the field of growth disorders, rare endocrine diseases and childhood obesity. Past and present board member of national as well as international quality registries.
PhD, Professor in Bioorganic Chemistry at Lund Institute of Technology at Lund University. The research is focused towards the use of small sugar molecules in anti-tumor treatment as well as physical-organic aspects of carbohydrates. Past and present innovator and board member in startup companies. Author of textbooks in Organic Chemistry. Key contributor to Adenovir Pharma AB.
MD, PhD, Professor/consultant in Cardiology/ Interventional cardiology (PCI), Head of Department of Cardiology, Lund University Hospital. Head of the research unit Molecular Cardiology, a leading group in cardiovascular research focusing on extracellular nucleotides and their receptors.
MD, PhD, Professor in Dermatology at Sahlgrenska Academy, University of Gothenburg. World leading researcher in dermatology with a special interest in Mycology and Dermato-Pharmacology. Innovator and former board member of Ambria Dermatology AB and innovator in Trophea AB.
M.Sc., chairman of Diaprost AB and Interket AS. Former CEO of Perstorp AB.
Maria Alquist Hegbrant
MD, Medical Director, Global Renal Medical Affairs, Baxter Healthcare. Former Vice President Global Medical & Scientific Support, Gambro. Senior Nephrologist and Internist, broad experience from clinical medicine, medical device and healthcare industry. Served as expert member in the Swedish Foundation for Strategic Research life science grant committees.
MD, PhD, Professor emeritus of Endocrinology at Sahlgrenska Academy, University of Gothenburg. Chairman of InternetMedicin AB.
M.Sc. in Biomedicine and Toxicology, has more than 30 years of professional experience from regulatory affairs, drug development and business development. Owner and CEO of Scandinavian Regulatory Services AB.
MD, PhD, Professor and senior consultant in Cardiothoracic Surgery at the Institute of Medicine, Sahlgrenska Academy, University of Gothenburg. Research interest in haemostasis, thrombosis and cardiovascular epidemiology. Author of more than 150 peer-reviewed scientific papers. Previous chairman of the SWEDEHEART registry.
MD, PhD, Professor of Endocrinology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg and Senior consultant Department of Endocrinology, Sahlgrenska University Hospital. Editor of the European Journal of Endocrinology, president of the Growth Hormone Research Society. Board member of Trophea AB. Innovator of AcuCort AB, DuoCort Pharma AB and Trophea AB.
M.Sc. (Pharm.) Solid experience from international marketing and drug development/clinical research. Leadership positions within Pharmacia, among others as Vice President and Business Manager for growth hormone. Former chairman of Jederstrom Pharmaceuticals. Co-founder of TKT-Europe-5S. Board member of Centogene AG and Glactone Pharma AB.
M.Sc. (Pharm) University of Uppsala. CEO of GMP consulting company, TQ Kvalitetskonsult AB. Licensed Qualified Person with focus on quality systems and auditing according to cGMP in EU, USA and Asia. Board member of AcuCort AB and Trophea AB. Co-founder and board member of QP Support AB. Co-founder of Dilafor AB.
M.Sc., PhD, Professor in Medical and Chemical Microsensors at the Biomedical Engineering, Lund University. Innovator, founder and board member in several technology companies.
LL.M, Senior Partner in the human venture capital company Lavindia AB. General Counsel experiences of Pharmacia Group, Active Biotech AB and SBL Vaccin AB and other extensive experience from various senior positions. Chairman of Trophea, board member of Adenovir Pharma AB, Cebix Sweden AB, Jatab Care AB, Scandinavian Biopharma Holding AB, Synphora AB and Lavindia AB.
PhD (organic synthesis, pharmaceutical science). Researcher at Lund Institute of Technology at Lund University. Involved in early development phase in Adenovir Pharma AB.
Professor of Toxicology at Karolinska Institutet. Presently involved in establishing Swedish Toxicology Sciences Research Center (Swetox). Was until 2012 Vice President and Head of Safety Assessment at Astra and AstraZeneca globally being responsible for all preclinical safety. Was before joining Astra Professor of Biochemical Toxicology at Karolinska Institutet. Has more than 200 publications in the areas of drug metabolism and mechanistic toxicology.
PhD, Associate Professor in Physiology, Lund University. Head Pipeline Sourcing Senior Director, LEO Pharma A/S. Former Director Strategic Planning and Business Development at AstraZeneca, several senior leadership positions at Pharmacia, Medical Director at Perstorp Pharma and Head of Preclinical R&D at Gambro. Board of Director of Genovis. Board member of Oncorena Holding AB.
MD, PhD, Professor at the Department of Internal Medicine, Sahlgrenska Academy, University of Gothenburg. Internationally recognized and award winning researcher in metabolic bone diseases and innovator in Trophea AB. Former chairman of P.U.L.S. AB.
Daniel S. Olsson
M.Sc., MD, PhD. Associate Professor at the Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg. Research field: Pituitary tumours, hormonal replacement therapy and discovering novel tumour markers connected to patient outcome. Board member of AcuCort AB.
MD, PhD, Professor of Oncology, Department of Oncology, Clinical Sciences, Lund University. Research interest in cancer epidemiology, cancer genetics, tumour biology, cancer prognosis and therapy. Published more than 500 scientific papers. Board member of Oncorena Holding AB.
Market economist. Runnberg has held senior executive positions in several international medtech companies including Gambro and HemoCue in Sweden; Diatek Medical Technologies, Block Medical and HemoCue, Inc. in California, USA and Vidacare B.V. in the Netherlands. Presently he is an industrial advisor to the Swedish private equity fund Valedo, engaged in the Clinical Innovation Fellowships program at KTH, Stockholm and a board member at Medicon Bridge in Lund. Former chairman of P.U.L.S. AB.
DVM, PhD, former consulting professor in Experimental Obstetrics and Gynecology at Uppsala University, Associate Professor in Pharmacology at the Veterinary Faculty of SLU (Swedish University of Agricultural Sciences). Former research director at Pharmacia, Perstorp, Novo Nordisk, Head of Clinical Operations at Quintiles, Vice President at CDC, Director at the Centre for Research on Pharmaceuticals at Lund University and board member of Vinnova's national program for pharmaceuticals, biotechnology and medical technology.
M.Sc, PhD, Professor in Organic Chemistry, Faculty of Science, Lund University. Major research fields are biologically active secondary metabolites and medicinal chemistry. Author or co-author of more than 420 publications in scientific journals, 30 patents/patent applications, and 5 text books in organic chemistry/chemical toxicology. Board member of P.U.L.S. AB and Glactone Pharma AB. Innovator in multiple PULS project companies.
MD, PhD, Senior Consultant, Head of Antenatal Health care and Associate Professor, Department of Obstetrics & Gynecology, Skåne University Hospital, specialized in high risk pregnancy. Regional Maternal Health Care Consultant in Skåne, Sweden. Developed national guidelines for antenatal health care. Board member of “International Society of the Study of Hypertension in Pregnancy”. Higher education in Health Economy. More than 20 publications.
MD, PhD, CEO of Oncorena. Former global Vice President Strategy, AstraZeneca Oncology & Infection. Professor, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg. CEO of Innoext AB. Board Director of Diaprost AB and Stayble Therapeutics AB. Chairman of Glactone Pharma AB and LIDDS AB. Innovator in Trophea AB.
MD, Clinical Innovations Fellow at Karolinska Institutet and KTH. Experience from global health/management research through Harvard Center for Health and the Global Environment, in addition to neurological research at University of Gothenburg. Innovator and co-founder of LARA Diagnostics. Former vice president of The Swedish Society of Medicine for young MDs.
M.Sc. Pharmacy with extensive senior experience of pharmaceutical research and development from roles such as Global Head and Vice President Clinical Development within AstraZeneca and Global Head and Vice President Pharmaceutical and Analytical R&D, AstraZeneca. Presently board member and advisor in life science. Board member of Adenovir Pharma AB.